Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.26 -0.56 (-2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Analysts Says Stat News Article Adds Uncertainty To Sarepta's SRP-9001, But Offers Buying Opportunity Around The Weakness ↗

April 13, 2023

Via Benzinga

FDA Staff Had Inclination Towards Rejecting Sarepta Duchenne Gene Therapy ↗

April 13, 2023

Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ: SRPT) closely watched gene therapy for Duchenne muscular dystrophy.

Via Benzinga

Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy ↗

April 13, 2023

According to a report, some staffers wanted to reject the highly watched drug.

Via Investor's Business Daily

Why Is Merck (MRK) Stock Up Today? ↗

April 13, 2023

Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda.

Via InvestorPlace

Why Is BigBear.ai (BBAI) Stock Down 5% Today? ↗

April 13, 2023

BigBear.ai (BBAI) stock is taking a beating on Thursday after the AI company announced the details of a public stock offering.

Via InvestorPlace

Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today? ↗

April 13, 2023

Sarepta Therapeutics (SRPT) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs.

Via InvestorPlace

TD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To Know ↗

March 22, 2023

Via Benzinga

The Latest Analyst Ratings for Sarepta Therapeutics ↗

March 22, 2023

Via Benzinga

Sarepta Therapeutics' FDA Adcomm Puts Some Risk, With Potential Approval: Analyst ↗

March 17, 2023

Via Benzinga

Why Sarepta Therapeutics Stock Is Tumbling Today ↗

April 13, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower Thursday on the heels of a report suggesting some U.S. Food and Drug Administration staff had opposition towards Sarepta gene therapy...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 13, 2023

Via Benzinga

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

April 10, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shareholder Notice: Investigation over Potential Securities Laws Violations ↗

April 10, 2023

San Diego, CA -- (SBWIRE) -- 04/10/2023 -- Sarepta Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023

April 10, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

April 09, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

2 Top Growth Stocks That Could Soar This Spring ↗

April 06, 2023

Exciting news on the way for both of these companies could send their stock prices screaming higher.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗

April 04, 2023

Via Benzinga

ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

April 02, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the Firm

March 29, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗

March 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

Via InvestorPlace

3 Up-and-Coming Growth Stocks to Buy Right Now ↗

March 25, 2023

These companies are small now but could grow much larger over time.

Via The Motley Fool

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

March 24, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

March 23, 2023

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process ↗

March 21, 2023

The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood...

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation

March 21, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Why did Sarepta Therapeutics Stock Plummet?

March 21, 2023

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

Via MarketBeat

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 17, 2023

Via Benzinga

Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗

March 17, 2023

A market rally is underway, but bank stocks kept tumbling.

Via Investor's Business Daily

Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 17, 2023

Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp.

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today